Sandu Pharmaceuticals (524703) Q2 25/26 earnings summary

Executive summary

• Unaudited standalone financial results for the quarter and half year ended 30th September 2025 were reviewed and approved by the Board on 12th November 2025.

• Financials are prepared in accordance with Indian Accounting Standards (Ind AS) and SEBI regulations.

Financial highlights

• Revenue from operations for Q2 FY26 was ₹1,762.11 lakhs, up from ₹1,669.90 lakhs in Q1 FY26 and ₹1,766.91 lakhs in Q2 FY25.

• Net profit for Q2 FY26 stood at ₹52.43 lakhs, compared to ₹22.33 lakhs in Q1 FY26 and ₹50.02 lakhs in Q2 FY25.

• Total comprehensive income for Q2 FY26 was ₹66.31 lakhs, compared to ₹32.66 lakhs in Q1 FY26 and ₹67.74 lakhs in Q2 FY25.

• Earnings per share (basic and diluted) for Q2 FY26 was ₹0.54, up from ₹0.23 in Q1 FY26.

Outlook and guidance

• Management evaluates performance based on revenue and operating income from a single segment: Ayurvedic Proprietary Medicines.